MPI Research has established a strong reputation as one of the most responsive preclinical CRO’s in the industry, especially within the small pharmaceutical and biotech arena. As part of a program seeking to improve services for this important group of Sponsors, MPI Research recently established non-naïve colonies of canines and primates to support individual pharmacokinetic screening studies. MPI Research has maintained a significant naïve primate colony allowing for rapid initiation of toxicology evaluations. Having acclimated primates available reduces the pre-study time by seven weeks, supporting the MPI Research philosophy of having rapid study initiations to aid Sponsors in reducing product time to market.

MPI Research has maintained Sponsor owned canine and primate colonies for many years. These colonies have supported high throughput in vivo drug candidate screening programs for both large and small pharmaceutical Sponsors needing to perform dozens to hundreds of pharmacokinetic studies annually. Acknowledging that many smaller companies do not have the need for a large volume of studies but still need rapid starts at reasonable costs, MPI Research established the new colonies of canines and primates. Now pharmacokinetic studies can be performed on an individual basis faster and at much lower costs than purchasing naïve animals and waiting for facility acclimation.

David G. Serota, Ph.D., D.A.B.T., Director of Toxicology commented, “We felt this was an important service to offer our Sponsors that need rapid study initiation at reasonable costs. Many of our Sponsors have asked us for a lower cost way to provide individual pharmacokinetic screening studies. We can now provide pharmacokinetic profiling services to all Sponsors at reasonable costs. This nicely complements the naïve primate colony MPI Research maintains for rapid initiation of primate toxicology studies. At MPI Research, we understand the time and financial pressures our Sponsors face. This is just one more way we can help them bring their products to market faster and more cost effectively.”

MPI Research exists to provide comprehensive non-clinical research that meets the requirements of pharmaceutical, medical device, animal health and chemical companies as well as governmental agencies as we partner together to bring safer, healthier products to the world. MPI Research employees specialize in a wide variety of scientific disciplines including toxicology, pharmacology, metabolism, pathology, clinical pathology, reproductive and developmental biology, veterinary science, neuroscience, experimental therapeutics, immunotoxicology, analytical chemistry, computer science, regulatory science, and statistics.

Home | News